ArticleBMC complementary medicine and therapies2026
Phytochemical and antidiabetic evaluation of Bauhinia tomentosa L. aerial parts.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMembers of the genus Bauhinia L., commonly known as cow's hoof, are important species in the family Fabaceae and are traditionally used to treat diabetes and other diseases. This study aimed to identify antidiabetic bioactive compounds from Bauhinia tomentosa aerial parts via bioassay-directed fractionation.
methodsDetermination of serum glucose and insulin levels was conducted on nicotinamide + STZ-induced diabetic rats treated with different fractions via a glucose oxidase assay kit and a rat insulin ELISA kit. In addition, GLUT4 protein levels in muscle homogenates were quantified via an ELISA kit. The ethyl acetate (EtOAc) fraction (the most active fraction) was fractionated via column chromatography (CC), and the isolated compounds were identified on the basis of their spectroscopic data. Additionally, the EtOAc fraction was characterized via LC‒QTOF‒MS/MS analysis. All the isolated compounds were evaluated for their antioxidant, α-glucosidase, and α-amylase inhibitory activities.
resultsThe EtOAc fraction markedly reduced the serum glucose level in the nicotinamide + STZ-induced type 2 diabetic rats (136.6 ± 12.17 mg/dL). Moreover, it showed a significant increase in serum insulin level (0.344 ± 0.04 µIU/mL). Four compounds (1-4) were isolated, of which luteolin showed potent inhibition of α-amylase activity, with an IC50 value of 19.32 ± 1.046 µM, as well as significant DPPH scavenging capacity. The LC-QTOF-MS/MS profiling validated the phytoconstituent composition and confirmed its chemotaxonomic relationship with closely related species.
conclusionsThe antidiabetic effects of EtOAc fraction and its isolates may be attributed to its insulinotropic, antioxidant, and carbohydrate-hydrolysing enzyme inhibitory activities. Luteolin has been shown to be at least partially responsible for the antidiabetic activity of B. tomentosa.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.